Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses

实验进化的痘苗突变在拮抗细胞防御中的作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): In addition to their medical importance as pathogens, vaccine vectors and oncolytic agents, poxviruses offer tractable model systems for discovering fundamental molecular and evolutionary mechanisms underlying the "arms races" between viruses and the host cells they parasitize. These conflicts drive rapid evolution of host and viral proteins and can create species barriers to viral transmission. One such case is the dsRNA-activated protein kinase R (PKR) pathway, which has broad antiviral activity but can be blocked, in a species-specific manner, by a variety of viral factors. Experimental evolution coupled with deep sequencing technology offers a powerful strategy for uncovering new factors and mechanisms underlying the arms race between PKR and its antagonists. For example, serial passage of a vaccinia virus (VV) mutant that encodes an antagonist that only weakly blocks PKR in one cell type yielded progeny viruses that were able to replicate much more efficiently not only in the cells used for the serial passage but also in cells from other species. Further studies revealed that amplification of the gene encoding the weak antagonist or mutations in either of two other VV genes, A24R and A35R, neither of which has previously been implicated as a modulator of the PKR pathway, dramatically improves VV replication in cells from multiple species. The proposed studies aim to elucidate the mechanisms by which mutations in A24R and A35R enable VV overcome the PKR and related host defense systems. Thus, this project will reveal new insights into the functions of these conserved poxvirus genes and into the roles and regulation of the PKR pathway and its VV antagonists. More generally, the results will aid in understanding how large DNA viruses can evolve to overcome host defenses and will have implications for understanding the risks and barriers to cross species transmission of viruses.
描述(由申请人提供):除了它们作为病原体、疫苗载体和溶瘤剂的医学重要性外,痘病毒还提供了易于处理的模型系统,用于发现病毒与其寄生的宿主细胞之间潜在的基本分子和进化机制。这些冲突促使宿主和病毒迅速进化 蛋白质,并可能对病毒传播造成物种障碍。其中一种情况是dsRNA激活的蛋白激酶R(PKR)途径,它具有广泛的抗病毒活性,但可以被各种病毒因子以物种特有的方式阻断。实验进化与深度测序技术相结合,为揭示PKR及其拮抗者之间军备竞赛的新因素和新机制提供了强有力的策略。例如,牛痘病毒(VV)突变体连续传代,其编码的拮抗剂仅弱地阻断一种细胞类型中的PKR,产生的后代病毒不仅能够在用于连续传代的细胞中更有效地复制,而且在其他物种的细胞中也能够更有效地复制。进一步的研究表明,编码弱拮抗剂的基因的扩增或另外两个VV基因A24R和A35R的突变(这两个基因以前都没有被认为是PKR途径的调节器)显著地改善了VV在多个物种的细胞中的复制。这些研究旨在阐明A24R和A35R突变使VV战胜PKR和相关宿主防御系统的机制。因此,该项目将揭示这些保守的痘病毒基因的功能以及PKR途径及其VV拮抗剂的作用和调节。更广泛地说,这些结果将有助于理解大型DNA病毒如何进化来克服宿主防御,并将对理解病毒跨物种传播的风险和障碍产生影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADAM P. GEBALLE其他文献

ADAM P. GEBALLE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADAM P. GEBALLE', 18)}}的其他基金

Evolution and mechanism of restriction of herpesviruses by MxB
MxB限制疱疹病毒的进化和机制
  • 批准号:
    10667144
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
Roles and regulation of polyamines during HCMV infection
多胺在 HCMV 感染过程中的作用和调节
  • 批准号:
    10308688
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses
巨细胞病毒拮抗宿主细胞防御的进化和机制
  • 批准号:
    10630815
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Roles and regulation of polyamines during HCMV infection
多胺在 HCMV 感染过程中的作用和调节
  • 批准号:
    10593450
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Evolution and mechanisms of cytomegalovirus antagonism of host cell defenses
巨细胞病毒拮抗宿主细胞防御的进化和机制
  • 批准号:
    10376227
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10434692
  • 财政年份:
    2019
  • 资助金额:
    $ 22万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10005407
  • 财政年份:
    2019
  • 资助金额:
    $ 22万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10188583
  • 财政年份:
    2019
  • 资助金额:
    $ 22万
  • 项目类别:
Optimizing Immunity and Maternal Host Defense Against Congenital Cytomegalovirus Infection
优化免疫和母体宿主防御先天性巨细胞病毒感染的能力
  • 批准号:
    10626882
  • 财政年份:
    2019
  • 资助金额:
    $ 22万
  • 项目类别:
Roles of Experimentally Evolved Vaccinia Mutations in Antagonizing Cell Defenses
实验进化的痘苗突变在拮抗细胞防御中的作用
  • 批准号:
    8848032
  • 财政年份:
    2014
  • 资助金额:
    $ 22万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 22万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 22万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 22万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 22万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了